FDA018-ADC is named as an intervention in 2 current clinical trials in our China register. None are recruiting at the moment. The most common phase is Phase 3. The lead sponsor is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. The most-studied condition is Triple Negative Breast Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
NCT06519370 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
|
Phase 3 | Active, closed | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd | China |
|
A Study of FDA018-ADC in Patients With Advanced Solid Tumors
NCT05174637 · ClinicalTrials.gov ↗ · Advanced/ Metastatic Solid Tumors
|
Phase 1 | Active, closed | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name FDA018-ADC (also registered as F0024) as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how FDA018-ADC works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how FDA018-ADC works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists FDA018-ADC (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.